GlassScriptPhysician profile
Cynthia Chow
NPI 1326048554
$2,826.54
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,977 · 2020: $217 · 2021: $328 · 2022: $304.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $534.49 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $458.38 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $332.61 | 2019-2022 | |
| Almirall LLC | $238.46 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $200.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $163.81 | 2019-2022 | |
| Promius Pharma LLC | $124.99 | 2019 | |
| Celgene Corporation | $124.98 | 2019 | |
| Aclaris Therapeutics, INC. | $124.57 | 2019 | |
| Pfizer INC. | $115.09 | 2019 | |
| Janssen Biotech, INC. | $111.81 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $97.62 | 2019 | |
| Leo Pharma INC. | $66.20 | 2019-2022 | |
| Incyte Corporation | $51.75 | 2022 | |
| Lilly USA, LLC | $25.87 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $22.23 | 2021 | |
| Dermira, INC. | $19.27 | 2020 | |
| Galderma Laboratories, L.P. | $13.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.